Bicycle Therapeutics
Bicycle Therapeutics

Genentech Bets on Bicycle-Based Therapies

Genentech, a subsidiary of the Roche Group (OTCMKTS: RHHBY), is betting big on a collaboration effort with Bicycle Therapeutics plc (NASDAQ: BCYC). The exclusive collaboration agreement between the two biotechnology companies hopes to develop and commercialize Bicycle-based immuno-oncology therapies against multiple targets. Genetech will pay $30 million upfront to Bicycle Therapeutics with a potential $1.7 […]

biotech
biotech

A Good Start for Biotech in 2020

Early in January 2019, Bristol-Myers Squibb‘s (NYSE: BMY) $74 billion acquisition of Celgene Corporation dominated the headlines. But despite that big deal, 2019 was a rather lackluster year for the Biotechnology sector. However, the opening quarter of 2020 is showing some promise. This year’s J.P. Morgan Healthcare Conference came and went without any major announcements, […]

2019’s Biggest Healthcare Deals, by Sector

2020 has just begun, which means it’s time to look back at the healthcare M&A landscape of 2019. Just three days into the new year, nearly 1,780 deals are already on the books for 2019. More deals will turn up as we search our many sources, but the number likely won’t top the record of […]

Thermo Fisher
Thermo Fisher

Cancer Treatments Are Driving Biopharmaceutical M&A

It’s been a busy year for mergers and acquisitions in the Biotechnology and Pharmaceutical industries. Combined spending on M&A is close to $268 billion mid-way through December, with 229 transactions reported. Although the number of deals is 34% lower than 2018’s combined total of 345, spending skyrocketed 62%, from just $165 billion in all of […]

vaccines
vaccines

GSK Divests Two Travel Vaccines

GlaxoSmithKline plc (NYSE: GSK) announced recently it is selling two travel vaccines to Bavarian Nordic for $334.7 million upfront, plus a potential $1.06 billion in milestone payments. The sale included rabies vaccine Rabipur (tradename Rabavert in the United States) and Encepur, for the prevention of tick-borne encephalitis. GSK obtained the vaccines as part of a 2015 deal […]

Ra Pharmaceuticals
Ra Pharmaceuticals

Ra Pharmaceuticals Targeted in $2.1 Billion Acquisition

The global biopharmaceutical company UCB (Brussels: UCB) announced it is acquiring Ra Pharmaceuticals (NASDAQ: RARX) for $2.1 billion. Ra Pharma is a clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of serious diseases caused by excessive or uncontrolled activation of the complement system, a critical component of the innate immune system. Ra Pharmaceuticals shareholders […]

Ra Pharmaceuticals
Ra Pharmaceuticals

Alder BioPharmaceuticals Merges with H. Lundbeck in $1.95 Billion Deal

H. Lundbeck A/S (OMX: LUN), the specialty pharmaceutical giant based in Denmark, announced its first acquisition in over a year. The company revealed it was buying Alder BioPharmaceuticals (NASDAQ: ALDR), a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. One product candidate is ALD1910, a monoclonal […]

gene-editing
gene-editing

Gene-Editing Firm Semma Acquired by Vertex

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) purchased another gene-editing biotech company last week, marking its fourth announced transaction of 2019. The pharmaceutical giant bought Semma Therapeutics for $950 million in an all-cash transaction for all of the company’s outstanding shares. Semma leverages stem cell-derived human islets to research potentially cures for type 1 diabetes. The biotech firm will become a […]

Ra Pharmaceuticals
Ra Pharmaceuticals

Agilent Acquires BioTek Instruments

Agilent Technologies (NYSE: A) announced its largest deal ever in July 2019. The Santa Clara, California-based biotech purchased privately held BioTek Instruments for nearly $1.2 billion. Agilent provides bio-analytical solutions and services to the life sciences, diagnostics, and genomics, chemical analysis, communications and electronics industries worldwide. On a trailing 12-month basis it generated revenue of […]

Ra Pharmaceuticals
Ra Pharmaceuticals

Array BioPharma Grabbed By Pfizer for $11.4 Billion

With AbbVie Inc.’s  (NYSE: ABBV) surprise $87 billion bid for Allergan plc (NYSE: AGN) dominating headlines this week, you’d be forgiven for forgetting Pfizer (NYSE: PFE) just bought Array BioPharma (NASDAQ: ARRY) for $11.4 billion only days before. It’s the pharmaceutical giant’s biggest deal of the year thus far in announced dollar volume, and only second behind the aforementioned […]